レノックス・ガストー症候群治療薬の世界市場レポート (2025年)

レノックス・ガストー症候群治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で19億1,000万米ドルに成長します。予測期間中の成長は、精密医療の重視、新興国市場におけるヘルスケアインフラの拡大、臨床試験数の増加、償還政策の改善、希少疾患の研究開発投資の増加、遺伝子検査による診断率の上昇などに起因すると考えられます。予測期間における主な動向としては、診断技術の革新、ドラッグデリバリー技術の発展、バイオマーカー同定の進展、創薬における人工知能の活用、次世代シーケンサー技術の開発、標的遺伝子治療の創出などが挙げられます。

小児てんかんを重視する傾向が強まっており、今後数年間でレノックス・ガストー症候群治療薬市場の成長を大きく押し上げると予想されます。小児てんかんは、小児期に発作を繰り返す神経疾患であり、新生児期や乳児期の脳損傷の割合が増加していることから、その有病率が上昇しています。小児てんかんに焦点を当てることで、早期介入の重要性が強調され、レノックス・ガストー症候群治療薬の必要性が高まっています。特殊な薬剤は、制御困難なてんかん発作を管理し、てんかんを持つ小児の発達遅滞を防ぐために不可欠です。このことは、小児てんかん特有の神経学的ニーズに対応した治療法の必要性を強調しています。例えば、2024年5月、米国疾病予防管理センター（CDC）は、2021年と2022年に18歳以上の米国成人約290万人が活動性てんかんに罹患し、米国の成人人口の約1％を占めると報告しました。その結果、小児てんかんに対する注目の高まりがレノックス・ガストー症候群治療薬市場の成長を後押ししています。

レノックス・ガストー症候群治療薬市場の主要プレーヤーは、規制当局の支持を獲得し、市場独占権を確保し、この希少かつ重篤な疾患に対する治療の商業化を促進するため、希少疾病用医薬品指定の進展にますます注力しています。希少疾病用医薬品の指定は、特定の地域で20万人未満しか罹患していない希少疾病や疾患のために開発された医薬品に、FDAなどの規制当局が与える特別なステータスです。例えば、米国の製薬会社マリナス・ファーマシューティカルズ・インクは2023年3月、レノックス・ガストー症候群（LGS）の治療薬としてガナキソロンにFDAから希少疾病用医薬品の指定（ODD）を受けたと発表しました。LGSは、小児期に発症し、難治性のてんかん発作と神経発達障害を特徴とする重篤なてんかんです。この指定には、承認後の市場独占権、FDA申請費用の免除、適格な臨床試験に対する税額控除などの利点があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ：金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のレノックス・ガストー症候群治療薬市場：PESTEL分析（政治・社会・技術・環境・法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のレノックス・ガストー症候群治療薬市場：成長率分析
• 世界のレノックス・ガストー症候群治療薬の市場規模・成長率：実績値、2019～2024年
• 世界のレノックス・ガストー症候群治療薬の市場規模・成長率：予測値、2024～2029年、2034年
• 世界のレノックス・ガストー症候群治療薬市場：総有効市場（TAM）

第6章 市場セグメンテーション

• 世界のレノックス・ガストー症候群治療薬市場：薬剤の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 中枢神経抑制剤
• 抗けいれん薬
• ペランパネル
• カンナビジオール
• 神経再生ペプチド2945
• その他の種類の薬剤
• 世界のレノックス・ガストー症候群治療薬市場：投与経路別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 経口
• 注射
• 鼻腔内
• 局所
• 世界のレノックス・ガストー症候群治療薬市場：治療用途、実績値・予測値、2019～2024年、2024～2029年、2034年
• 長期治療
• 急性発作の治療
• 補助療法
• 救急薬
• 世界のレノックス・ガストー症候群治療薬市場：流通チャネル別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のレノックス・ガストー症候群治療薬市場：エンドユーザー別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院・診療所
• 在宅医療
• 専門てんかんセンター
• 製薬・小売薬局
• 世界のレノックス・ガストー症候群治療薬市場：中枢神経抑制剤の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• ベンゾジアゼピン
• バルビツール酸
• 睡眠導入剤
• 世界のレノックス・ガストー症候群治療薬市場：抗けいれん薬の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• バルプロ酸
• ラモトリギン
• トピラマート
• フェルバメート
• ルフィナミド
• 世界のレノックス・ガストー症候群治療薬市場：ペランパネルの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• ブランド処方
• ジェネリック医薬品
• 世界のレノックス・ガストー症候群治療薬市場：カンナビジオールの種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 植物由来カンナビジオール
• 合成カンナビジオール
• 世界のレノックス・ガストー症候群治療薬市場：神経再生ペプチド2945の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• ペプチドベースの単剤療法
• 併用療法
• 世界のレノックス・ガストー症候群治療薬市場：その他の薬剤の種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• 免疫グロブリン
• ケトジェニック剤

第7章 地域別・国別分析

• 世界のレノックス・ガストー症候群治療薬市場：地域別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 世界のレノックス・ガストー症候群治療薬市場：国別、実績値・予測値、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レノックス・ガストー症候群治療薬市場：競合情勢
• レノックス・ガストー症候群治療薬市場：企業プロファイル
  • Pfizer Inc.（概要、製品・サービス、戦略、財務分析）
  • Johnson & Johnson（概要、製品・サービス、戦略、財務分析）
  • F. Hoffmann-La Roche AG（概要、製品・サービス、戦略、財務分析）
  • AbbVie Inc.（概要、製品・サービス、戦略、財務分析）
  • Sanofi SA（概要、製品・サービス、戦略、財務分析）

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• UCB SA
• Eisai Co Ltd.
• Amneal Pharmaceuticals Inc.
• Supernus Pharmaceuticals Inc.
• Lundbeck A/S
• GW Pharmaceuticals Plc
• Ultragenyx Pharmaceutical Inc.
• Marinus Pharmaceuticals Inc.
• Stoke Therapeutics Inc.
• Zynerba Pharmaceuticals Inc.
• Ovid Therapeutics Inc.

第32章 世界市場：競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

• レノックス・ガストー症候群治療薬市場：最新機会を提供する国（2029年）
• レノックス・ガストー症候群治療薬市場：最新機会を提供する部門（2029年）
• レノックス・ガストー症候群治療薬市場：成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競争戦略

第36章 付録

Lennox-Gastaut syndrome drug refers to medication specifically developed or prescribed to manage the seizures and other symptoms associated with this severe form of epilepsy. These medications work by adjusting brain chemistry to control irregular electrical activity, thus reducing the frequency and severity of seizures.

The main types of Lennox-Gastaut syndrome drugs include central nervous system depressants, anticonvulsants, perampanel, cannabidiol, neural regeneration peptide 2945, and others. Central nervous system depressants are drugs that lower brain activity, helping with seizure control and promoting relaxation. They can be administered orally, via injection, intranasally, or topically, and are used for long-term management, acute seizure treatment, adjunctive therapy, and as rescue medications. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in settings such as hospitals, clinics, home care, specialized epilepsy centers, and pharmaceutical retail outlets.

The lennox-gastaut syndrome drug market research report is one of a series of new reports from The Business Research Company that provides lennox-gastaut syndrome drug market statistics, including lennox-gastaut syndrome drug industry global market size, regional shares, competitors with an lennox-gastaut syndrome drug market share, detailed lennox-gastaut syndrome drug market segments, market trends and opportunities, and any further data you may need to thrive in the lennox-gastaut syndrome drug industry. The lennox-gastaut syndrome drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lennox-gastaut syndrome drug market size has grown strongly in recent years. It will grow from $1.30 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be credited to a rise in awareness of rare epileptic disorders, an increasing prevalence of pediatric epilepsy, better access to healthcare, enhanced investment in neurology research, and incentives provided by orphan drug designations.

The lennox-gastaut syndrome drug market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to a greater emphasis on precision medicine, the expansion of healthcare infrastructure in emerging markets, a higher number of clinical trials, improved reimbursement policies, increased investment in research and development for rare diseases, and rising diagnosis rates through genetic testing. Key trends in the forecast period include innovations in diagnostic technologies, advancements in drug delivery technology, progress in biomarker identification, the use of artificial intelligence in drug discovery, the development of next-generation sequencing technologies, and the creation of targeted gene therapies.

The growing emphasis on pediatric epilepsy is expected to significantly boost the growth of the Lennox-Gastaut syndrome drug market in the coming years. Pediatric epilepsy is a neurological condition marked by recurrent seizures in children, with its prevalence rising due to the increasing rates of neonatal and infant brain injuries, which can lead to the onset of epilepsy in early childhood. The focus on pediatric epilepsy reinforces the need for Lennox-Gastaut syndrome drugs by highlighting the importance of early intervention, as specialized medications are essential for managing hard-to-control seizures and preventing developmental delays in children with epilepsy. This underscores the demand for therapies tailored to address their specific neurological needs. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2021 and 2022, accounting for about 1% of the adult population in the United States. As a result, the rising attention on pediatric epilepsy is fueling the growth of the Lennox-Gastaut syndrome drug market.

Key players in the Lennox-Gastaut syndrome drug market are increasingly focusing on advancements in orphan drug designation to gain regulatory support, ensure market exclusivity, and expedite the commercialization of treatments for this rare and severe condition. Orphan drug designation is a special status granted by regulatory bodies, such as the FDA, to drugs developed for rare diseases or conditions that affect fewer than 200,000 individuals in a specific region. For example, in March 2023, Marinus Pharmaceuticals Inc., a U.S.-based pharmaceutical company, announced that the FDA had granted Orphan Drug Designation (ODD) to ganaxolone for treating Lennox-Gastaut syndrome (LGS). LGS is a severe form of epilepsy that begins in childhood and is marked by intractable seizures and neurodevelopmental impairment. This designation offers advantages including market exclusivity after regulatory approval, exemption from FDA application fees, and tax credits for eligible clinical trials.

In December 2024, H. Lundbeck A/S, a pharmaceutical company based in Denmark, acquired Longboard Pharmaceuticals for $2.6 billion. This acquisition expands Lundbeck's neurology and psychiatry portfolio by incorporating Longboard's promising pipeline of treatments for neurological diseases, including rare and orphan conditions. The move strengthens Lundbeck's position in the global market and enhances its research and development capabilities for central nervous system disorders. Longboard Pharmaceuticals Inc., a U.S.-based clinical-stage biopharmaceutical company, specializes in developing innovative, transformative medicines for Lennox-Gastaut syndrome.

Major players in the lennox-gastaut syndrome drug market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi SA, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, UCB SA, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Lundbeck A/S, GW Pharmaceuticals Plc, Ultragenyx Pharmaceutical Inc., Marinus Pharmaceuticals Inc., Stoke Therapeutics Inc., Zynerba Pharmaceuticals Inc., and Ovid Therapeutics Inc.

North America was the largest region in the lennox-gastaut syndrome drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lennox-gastaut syndrome drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lennox-gastaut syndrome drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lennox-gastaut syndrome (LGS) drug market consists of sales of corticosteroids, benzodiazepines, and sleep-inducing agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lennox-Gastaut Syndrome Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lennox-gastaut syndrome drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lennox-gastaut syndrome drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lennox-gastaut syndrome drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Central Nervous System Depressants; Anticonvulsants; Perampanel; Cannabidiol; Neural Regeneration Peptide 2945; Other Drug Types
• 2) By Route of Administration: Oral; Injection; Intranasal; Topical
• 3) By Therapeutic Use: Long-Term Management; Acute Seizure Treatment; Adjunctive Therapy; Rescue Medications
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By End-User: Hospitals And Clinics; Home Care Settings; Specialized Epilepsy Centers; Pharmaceutical Retail Pharmacies
• Subsegments:
• 1) By Central Nervous System Depressants: Benzodiazepines; Barbiturates; Sleep-Inducing Agents
• 2) By Anticonvulsants: Valproate; Lamotrigine; Topiramate; Felbamate; Rufinamide
• 3) By Perampanel: Branded Formulations; Generic Formulations
• 4) By Cannabidiol: Plant-Derived Cannabidiol; Synthetic Cannabidiol
• 5) By Neural Regeneration Peptide 2945: Peptide-Based Monotherapy; Combination Therapies
• 6) By Other Drug Types: Corticosteroids; Immunoglobulins; Ketogenic Agents
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lennox-Gastaut Syndrome Drug Market Characteristics

3. Lennox-Gastaut Syndrome Drug Market Trends And Strategies

4. Lennox-Gastaut Syndrome Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lennox-Gastaut Syndrome Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lennox-Gastaut Syndrome Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lennox-Gastaut Syndrome Drug Market Growth Rate Analysis
• 5.4. Global Lennox-Gastaut Syndrome Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lennox-Gastaut Syndrome Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lennox-Gastaut Syndrome Drug Total Addressable Market (TAM)

6. Lennox-Gastaut Syndrome Drug Market Segmentation

• 6.1. Global Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Central Nervous System Depressants
• Anticonvulsants
• Perampanel
• Cannabidiol
• Neural Regeneration Peptide 2945
• Other Drug Types
• 6.2. Global Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• Intranasal
• Topical
• 6.3. Global Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Term Management
• Acute Seizure Treatment
• Adjunctive Therapy
• Rescue Medications
• 6.4. Global Lennox-Gastaut Syndrome Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Lennox-Gastaut Syndrome Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Home Care Settings
• Specialized Epilepsy Centers
• Pharmaceutical Retail Pharmacies
• 6.6. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Central Nervous System Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benzodiazepines
• Barbiturates
• Sleep-Inducing Agents
• 6.7. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Valproate
• Lamotrigine
• Topiramate
• Felbamate
• Rufinamide
• 6.8. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Perampanel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Formulations
• Generic Formulations
• 6.9. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Cannabidiol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plant-Derived Cannabidiol
• Synthetic Cannabidiol
• 6.10. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Neural Regeneration Peptide 2945, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide-Based Monotherapy
• Combination Therapies
• 6.11. Global Lennox-Gastaut Syndrome Drug Market, Sub-Segmentation Of Other Drug Types,By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunoglobulins
• Ketogenic Agents

7. Lennox-Gastaut Syndrome Drug Market Regional And Country Analysis

• 7.1. Global Lennox-Gastaut Syndrome Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lennox-Gastaut Syndrome Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lennox-Gastaut Syndrome Drug Market

• 8.1. Asia-Pacific Lennox-Gastaut Syndrome Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lennox-Gastaut Syndrome Drug Market

• 9.1. China Lennox-Gastaut Syndrome Drug Market Overview
• 9.2. China Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lennox-Gastaut Syndrome Drug Market

• 10.1. India Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lennox-Gastaut Syndrome Drug Market

• 11.1. Japan Lennox-Gastaut Syndrome Drug Market Overview
• 11.2. Japan Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lennox-Gastaut Syndrome Drug Market

• 12.1. Australia Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lennox-Gastaut Syndrome Drug Market

• 13.1. Indonesia Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lennox-Gastaut Syndrome Drug Market

• 14.1. South Korea Lennox-Gastaut Syndrome Drug Market Overview
• 14.2. South Korea Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lennox-Gastaut Syndrome Drug Market

• 15.1. Western Europe Lennox-Gastaut Syndrome Drug Market Overview
• 15.2. Western Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lennox-Gastaut Syndrome Drug Market

• 16.1. UK Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lennox-Gastaut Syndrome Drug Market

• 17.1. Germany Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lennox-Gastaut Syndrome Drug Market

• 18.1. France Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lennox-Gastaut Syndrome Drug Market

• 19.1. Italy Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lennox-Gastaut Syndrome Drug Market

• 20.1. Spain Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lennox-Gastaut Syndrome Drug Market

• 21.1. Eastern Europe Lennox-Gastaut Syndrome Drug Market Overview
• 21.2. Eastern Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lennox-Gastaut Syndrome Drug Market

• 22.1. Russia Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lennox-Gastaut Syndrome Drug Market

• 23.1. North America Lennox-Gastaut Syndrome Drug Market Overview
• 23.2. North America Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lennox-Gastaut Syndrome Drug Market

• 24.1. USA Lennox-Gastaut Syndrome Drug Market Overview
• 24.2. USA Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lennox-Gastaut Syndrome Drug Market

• 25.1. Canada Lennox-Gastaut Syndrome Drug Market Overview
• 25.2. Canada Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lennox-Gastaut Syndrome Drug Market

• 26.1. South America Lennox-Gastaut Syndrome Drug Market Overview
• 26.2. South America Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lennox-Gastaut Syndrome Drug Market

• 27.1. Brazil Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lennox-Gastaut Syndrome Drug Market

• 28.1. Middle East Lennox-Gastaut Syndrome Drug Market Overview
• 28.2. Middle East Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lennox-Gastaut Syndrome Drug Market

• 29.1. Africa Lennox-Gastaut Syndrome Drug Market Overview
• 29.2. Africa Lennox-Gastaut Syndrome Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lennox-Gastaut Syndrome Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lennox-Gastaut Syndrome Drug Market, Segmentation By Therapeutic Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lennox-Gastaut Syndrome Drug Market Competitive Landscape And Company Profiles

• 30.1. Lennox-Gastaut Syndrome Drug Market Competitive Landscape
• 30.2. Lennox-Gastaut Syndrome Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Lennox-Gastaut Syndrome Drug Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company
• 31.5. UCB SA
• 31.6. Eisai Co Ltd.
• 31.7. Amneal Pharmaceuticals Inc.
• 31.8. Supernus Pharmaceuticals Inc.
• 31.9. Lundbeck A/S
• 31.10. GW Pharmaceuticals Plc
• 31.11. Ultragenyx Pharmaceutical Inc.
• 31.12. Marinus Pharmaceuticals Inc.
• 31.13. Stoke Therapeutics Inc.
• 31.14. Zynerba Pharmaceuticals Inc.
• 31.15. Ovid Therapeutics Inc.

32. Global Lennox-Gastaut Syndrome Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lennox-Gastaut Syndrome Drug Market

34. Recent Developments In The Lennox-Gastaut Syndrome Drug Market

35. Lennox-Gastaut Syndrome Drug Market High Potential Countries, Segments and Strategies

• 35.1 Lennox-Gastaut Syndrome Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lennox-Gastaut Syndrome Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lennox-Gastaut Syndrome Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer